Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.
NCT02970942 on ClinicalTrials.gov · last registry update 2021-11-16
An unusually large phase 2: 320 participants, more than double the 110 typical for the stage. Completed 13 February 2020. semaglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Enrollment
- 320
- Started
- 2016-11-30
- Primary completion
- 2020-02-13 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percentage of Participants With Non- Alcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 72 Weeks (Yes/No)
Conditions studied
Hepatobiliary Disorders · Non-alcoholic Steatohepatitis
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.